drugset / Trial / NCT02145104

Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

NCT02145104

Phase 3 Completed 286 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy

Timeline

Start
2014-06-17
Primary completion
2016-06-07
Completion
2016-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilnidipine Small molecule 5 mg
Subject Cilnidipine Small molecule 10 mg
Subject Valsartan Small molecule 160 mg